

Drug Injury Watch: New Federal Court Multidistrict Litigation (MDL) For Farxiga Lawsuits

(Posted by Tom Lamb at www.DrugInjuryWatch.com on March 8, 2017)

There have been drug injury lawsuits filed involving Farxiga (dapagliflozin) and Xigduo XR (dapagliflozin and metformin extended-release), which are relatively new diabetes medicines in the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors class of drugs.

Those lawsuits recently gave rise to a request for the consolidation of all Farxiga and Xigduo XR cases pending in the various federal court districts around the country before one judge. This legal motion is scheduled to be heard by United States Judicial Panel On Multidistrict Litigation (JPML) on March 30, 2017.

From this court document we get the following information about this proposed federal court multidistrict litigation, or MDL, for Farxiga and Xigduo XR:

- This motion for transfer involves eighteen pending cases in six district courts asserting similar claims....
- Each of these Actions arise from the same or similar operative facts and wrongful conduct alleging that, as a result of ingesting Farxiga, Plaintiffs have suffered sudden onset of life-threatening diabetic ketoacidosis (often in the setting of normal blood glucose levels), and/or acute renal failure, and/or pyelonephritis (kidney infection) and/or urosepsis and continue to suffer from the sequelae of these injuries. Farxiga (dapagliflozin) is a pharmaceutical drug used to treat Type 2 Diabetes. All of these injuries were the subject of recent FDA safety advisories....
- ... Judge [Lorna G.] Schofield in the Southern District of New York is already presiding over the vast majority of the Farxiga cases filed nationally. She has already conducted a pretrial conference to attempt to coordinate the cases pending before her. Continuing with that process would prevent any further delay in those cases. Further, Defendant Bristol-Myers Squibb has its principal place of business in New York....
- If the Panel should decide that transfer to the Southern District of New York is not warranted, Plaintiff requests in the alternative, Transfer to either the Eastern District of Pennsylvania before Judge Mitchell Goldberg, or the Southern District of Illinois before Judge Nancy J. Rosenstengel.

Be assured we will be watching for the JPML determination about whether or not to establish this Farxiga / Xigduo XR MDL.

[\[Read this article in full at original source\]](#)

Earlier Invokana / Farxiga / Jardiance articles by attorney Tom Lamb on the [Side Effects Blog](#):

- [Invokana Has New Warning About Risk Of Lower Limb Amputation In Canada](#)
 - [December 2016: FDA Requires Safety Warnings Label Change For Jardiance](#)
 - [Farxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning](#)
 - [Invokana / Farxiga / Jardiance: UTIs Then Urosepsis And Pyelonephritis](#)
 - [Invokana / Farxiga / Jardiance: Amputations; Lactic Acidosis; Ketoacidosis](#)
-

Attorney [Tom Lamb](#) represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.
<http://www.DrugInjuryWatch.com>